FindTrial
Sign In

Single-Cell Sequencing Elucidates Molecular Drivers of Malignant Evolution in Pan-Cancer Adenosquamous Carcinoma

Single-Cell Sequencing Elucidates Molecular Drivers of Malignant Evolution in Pan-Cancer Adenosquamous Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500099382
Enrollment
Unknown
Registered
2025-03-24
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pan-Cancer Adenosquamous Carcinoma

Interventions

Observation group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients pathologically diagnosed with adenosquamous carcinoma; (2) Availability of complete clinical data and patient follow-up records; (3) Availability of pathological specimens suitable for sequencing analysis (including tissue sections and blood samples).

Exclusion criteria

Exclusion criteria: (1) Incomplete clinical data or absence of key clinical parameters; (2) Pathological specimens failing to meet sequencing quality thresholds (e.g., RNA integrity number <7, tumor purity <60%); (3) Pathological diagnoses inconsistent with study scope, including but not limited to: Neuroendocrine tumors (ICD-O code 8240-8249) Mesenchymal tissue-origin tumors (e.g., sarcomas, ICD-O code 8800-8899) Tumors with indeterminate histopathological classification.

Design outcomes

Primary

MeasureTime frame
Tumor Mutational Burden;Drug Resistance-Associated Clonal Evolution;Overall Survival;Progression-Free Survival;—

Countries

China

Contacts

Public ContactZhong Wu

West China Hospital of Sichuan University

wuzhong0057@163.com+86 130 2833 1396

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026